Recursion Pharmaceuticals Inc Cl A (RXRX)

$5.00 +0.08 (1.63%)
Market Cap 2.00B
Revenue (ttm) 58.84M
Net Income (ttm) -463.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -788.00%
Debt to Equity Ratio 0.02
Volume 26,984,299
Avg Vol 25,242,035
Day's Range N/A - N/A
Shares Out 406.50M
Stochastic %K 36%
Beta 0.84
Analysts Sell
Price Target $7.17

Company Profile

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4...

Industry: Biotechnology
Sector: Healthcare
Phone: 385 269 0203
Fax: 801 821 2872
Address:
41 South Rio Grande Street, Salt Lake City, United States
jimbob3369
jimbob3369 Jun. 17 at 5:52 AM
$RXRX the patience it's taken to see this break past double digits and stay there
0 · Reply
anachartanalyst
anachartanalyst Jun. 16 at 8:02 PM
$RXRX https://anachart.com/wp-content/uploads/ana_temp/1750104111_soc-img.jpg
0 · Reply
3xMaster
3xMaster Jun. 16 at 7:35 PM
$RXRX took gains from low 4…. I’ll come back
1 · Reply
Investmike94
Investmike94 Jun. 16 at 6:55 PM
$RXRX
0 · Reply
fatpie68
fatpie68 Jun. 16 at 5:49 PM
That 35+% Short Interest is a drag on $RXRX but looking at the MACD on the weekly is very promising. Any good news should see a substantial bump in share price.
0 · Reply
Typhoon_3Mint
Typhoon_3Mint Jun. 16 at 4:11 PM
$RXRX
1 · Reply
classhopper
classhopper Jun. 16 at 3:50 PM
$RXRX hardly any downside here All upside potential SCREAMING BUY
0 · Reply
JarvisFlow
JarvisFlow Jun. 16 at 3:41 PM
Morgan Stanley has updated their rating for Recursion Pharmaceuticals ( $RXRX ) to Equal-Weight with a price target of 5.
0 · Reply
classhopper
classhopper Jun. 16 at 3:34 PM
$RXRX For my followers, I am not a financial advisor, but as I have been posting, today's buys are OKLO NBIS and RXRX
0 · Reply
TalkMarkets
TalkMarkets Jun. 16 at 3:32 PM
Recursion Pharmaceuticals Went Down 10% Week-Ending June 13th - Here's Why $RXRX https://talkmarkets.com/content/stocks--equities/recursion-pharmaceuticals-went-down-10-week-ending-june-13th-heres-why?post=503034&userid=166882
0 · Reply
Latest News on RXRX
Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

Jun 10, 2025, 6:14 AM EDT - 6 days ago

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Jun 6, 2025, 10:00 AM EDT - 10 days ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Recursion to Participate in Upcoming Investor Conferences

May 30, 2025, 8:00 AM EDT - 17 days ago

Recursion to Participate in Upcoming Investor Conferences

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 1:37 PM EDT - 6 weeks ago

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 6:00 AM EDT - 6 weeks ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

May 5, 2025, 4:02 AM EDT - 6 weeks ago

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

May 4, 2025, 12:45 PM EDT - 6 weeks ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Apr 28, 2025, 8:27 AM EDT - 7 weeks ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Apr 22, 2025, 8:34 PM EDT - 7 weeks ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Apr 16, 2025, 8:30 AM EDT - 2 months ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Apr 9, 2025, 8:00 AM EDT - 2 months ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Recursion to Participate in Upcoming Investor Conference

Apr 1, 2025, 8:00 AM EDT - 2 months ago

Recursion to Participate in Upcoming Investor Conference

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Mar 3, 2025, 11:19 AM EST - 3 months ago

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 1:16 PM EST - 3 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 28, 2025, 6:30 AM EST - 3 months ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Feb 24, 2025, 8:00 AM EST - 4 months ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Altitude Lab Startups Raise $154M in Capital

Feb 18, 2025, 11:00 AM EST - 4 months ago

Altitude Lab Startups Raise $154M in Capital

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Feb 13, 2025, 6:05 PM EST - 4 months ago

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Feb 5, 2025, 5:24 PM EST - 4 months ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Jan 7, 2025, 9:15 AM EST - 5 months ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Jan 6, 2025, 8:30 AM EST - 5 months ago

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Dec 20, 2024, 4:05 PM EST - 6 months ago

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Dec 12, 2024, 6:07 AM EST - 6 months ago

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Dec 9, 2024, 6:00 PM EST - 6 months ago

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Dec 9, 2024, 3:14 PM EST - 6 months ago

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Nov 20, 2024, 7:00 AM EST - 7 months ago

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion and Exscientia Shareholders Approve the Proposed Combination

Nov 13, 2024, 9:08 AM EST - 7 months ago

Recursion and Exscientia Shareholders Approve the Proposed Combination

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

Nov 12, 2024, 4:54 PM EST - 7 months ago

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Oct 30, 2024, 8:22 AM EDT - 8 months ago

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Oct 22, 2024, 8:00 AM EDT - 8 months ago

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

Oct 6, 2024, 2:00 PM EDT - 9 months ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EDIT EXAS

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Oct 2, 2024, 8:32 AM EDT - 9 months ago

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Oct 2, 2024, 8:00 AM EDT - 9 months ago

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Sep 4, 2024, 1:03 PM EDT - 10 months ago

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Recursion's blood vessel disorder drug meets main goal in mid-stage study

Sep 3, 2024, 8:11 AM EDT - 10 months ago

Recursion's blood vessel disorder drug meets main goal in mid-stage study

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

Aug 9, 2024, 9:00 AM EDT - 11 months ago

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

EXAI

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 8:25 AM EDT - 11 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

Aug 8, 2024, 5:37 PM EDT - 11 months ago

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

EXAI

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 2:41 PM EDT - 11 months ago

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Aug 8, 2024, 7:39 AM EDT - 11 months ago

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

Aug 8, 2024, 7:08 AM EDT - 11 months ago

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

EXAI

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

Aug 8, 2024, 1:32 AM EDT - 11 months ago

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

Aug 5, 2024, 4:01 PM EDT - 11 months ago

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Aug 1, 2024, 6:35 PM EDT - 11 months ago

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Jun 26, 2024, 10:07 PM EDT - 1 year ago

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Recursion Announces Proposed Offering of Class A Common Stock

Jun 26, 2024, 4:06 PM EDT - 1 year ago

Recursion Announces Proposed Offering of Class A Common Stock

Recursion CEO Chris Gibson talks integrating AI into drug development process

Jun 24, 2024, 6:18 PM EDT - 1 year ago

Recursion CEO Chris Gibson talks integrating AI into drug development process

Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data

Jun 24, 2024, 9:00 AM EDT - 1 year ago

Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data

Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day

jimbob3369
jimbob3369 Jun. 17 at 5:52 AM
$RXRX the patience it's taken to see this break past double digits and stay there
0 · Reply
anachartanalyst
anachartanalyst Jun. 16 at 8:02 PM
$RXRX https://anachart.com/wp-content/uploads/ana_temp/1750104111_soc-img.jpg
0 · Reply
3xMaster
3xMaster Jun. 16 at 7:35 PM
$RXRX took gains from low 4…. I’ll come back
1 · Reply
Investmike94
Investmike94 Jun. 16 at 6:55 PM
$RXRX
0 · Reply
fatpie68
fatpie68 Jun. 16 at 5:49 PM
That 35+% Short Interest is a drag on $RXRX but looking at the MACD on the weekly is very promising. Any good news should see a substantial bump in share price.
0 · Reply
Typhoon_3Mint
Typhoon_3Mint Jun. 16 at 4:11 PM
$RXRX
1 · Reply
classhopper
classhopper Jun. 16 at 3:50 PM
$RXRX hardly any downside here All upside potential SCREAMING BUY
0 · Reply
JarvisFlow
JarvisFlow Jun. 16 at 3:41 PM
Morgan Stanley has updated their rating for Recursion Pharmaceuticals ( $RXRX ) to Equal-Weight with a price target of 5.
0 · Reply
classhopper
classhopper Jun. 16 at 3:34 PM
$RXRX For my followers, I am not a financial advisor, but as I have been posting, today's buys are OKLO NBIS and RXRX
0 · Reply
TalkMarkets
TalkMarkets Jun. 16 at 3:32 PM
Recursion Pharmaceuticals Went Down 10% Week-Ending June 13th - Here's Why $RXRX https://talkmarkets.com/content/stocks--equities/recursion-pharmaceuticals-went-down-10-week-ending-june-13th-heres-why?post=503034&userid=166882
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jun. 16 at 3:22 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
InsightInvest00
InsightInvest00 Jun. 16 at 3:20 PM
$RXRX
0 · Reply
Spartangio
Spartangio Jun. 16 at 3:05 PM
$RXRX nvidia + recursion let it works
0 · Reply
ShadowBanningIsBad
ShadowBanningIsBad Jun. 16 at 2:06 PM
$RXRX went from 5.05 to 4.84.
1 · Reply
fatpie68
fatpie68 Jun. 16 at 1:19 PM
$RXRX has a double bottom and last week's decline that lost half of the prior week's increase, still closed above the 15-day EMA; so I'm confident we'll keep the weekly uptrend going. The weekly is what I'm watching more so than the daily and I'm adding at these cheap prices.
0 · Reply
classhopper
classhopper Jun. 16 at 1:11 PM
$RXRX looks to me RXRX is way way OVERSOLD and very very UNDERVALUED should VAULT up
1 · Reply
ShadowBanningIsBad
ShadowBanningIsBad Jun. 16 at 12:55 PM
$RXRX looks like prices are going to drop for a bit who knows what will happen at open.
1 · Reply
Spartangio
Spartangio Jun. 16 at 12:31 PM
$RXRX worth reading https://www.tradingview.com/chart/RXRX/8iZPfzmY-Why-Recursion-Pharmaceuticals-RXRX-Could-Be-the-NVDA-of-Biotech/
0 · Reply
classhopper
classhopper Jun. 16 at 12:20 PM
$RXRX should be UP. 30 today
0 · Reply
classhopper
classhopper Jun. 16 at 12:12 PM
$RXRX bargain basement BUY So cheap here BUY BUY BUY
0 · Reply
Moneyidea8
Moneyidea8 Jun. 16 at 5:15 AM
$RXRX shorts are our friends longs!. Esp when RXRX has several short term challenges, Shorts get us ultra low sp to load and add to our position. Just accumulate in chunks and ignore the noise if you have 10 yr time horizon. This one is worth taking the risk. Moving from 4 digit position to 5 digit. I don't check the sp on daily basis
1 · Reply
BioGem
BioGem Jun. 16 at 1:06 AM
$RXRX Due to the same reasons that I posted a while back, this stock continues to be an excellent short for another 60% down before year end.
2 · Reply